|1.||Terhaag, B: 3 articles (02/2005 - 07/2000)|
|2.||Kroemer, Heyo K: 2 articles (09/2004 - 02/2002)|
|3.||Siegmund, Werner: 2 articles (09/2004 - 02/2002)|
|4.||Zschiesche, Michael: 2 articles (09/2004 - 02/2002)|
|5.||Oertel, R: 2 articles (02/2001 - 07/2000)|
|6.||Merino, Virginia: 1 article (10/2011)|
|7.||Merino-Sanjuán, Matilde: 1 article (10/2011)|
|8.||Jiménez-Torres, Nicolás Víctor: 1 article (10/2011)|
|9.||Catalán-Latorre, Ana: 1 article (10/2011)|
|10.||Nácher, Amparo: 1 article (10/2011)|
|1.||Hypertension (High Blood Pressure)
03/01/1998 - "It can be concluded from the results that the once daily intake of talinolol in the dosage range of 100-200 mg/d shows a reliable efficacy in the treatment of essential hypertension accompanied by a noncritical safety profile."
01/01/1983 - "[The use of the cardioselective adrenergic beta 1-blockader cordanum in the treatment of arterial hypertension]."
11/01/1982 - "[Use of Cordanum in labile hypertension]."
01/01/2003 - "The primary objective of this double-blind, randomized, parallel-group study was to compare the influence ofthe selective beta1-receptor antagonists talinolol (100 mg) and atenolol (50 mg) on the lipid metabolism in hyperlipemic patients with mild to moderate hypertension after 12 weeks of treatment. "
04/01/1983 - "[Comparative evaluation of the hemodynamic effect of a single administration of cordanum and obzidan in patients with arterial hypertension]."
|2.||Body Weight (Weight, Body)
02/01/2002 - "Because talinolol is marketed as a racemate, we reevaluated the serum-concentration time profiles of talinolol of a previously published study with single intravenous (30 mg) and repeated oral talinolol (100 mg for 14 days) before and after comedication of rifampicin (600 mg per day for 9 days) in eight male healthy volunteers (age 22-26 years, body weight 67-84 kg) with respect to differences in the kinetic profiles of the two enantiomers S(-) talinolol and R(+) talinolol. "
07/01/2000 - "Pharmacokinetics of digoxin (0.5 mg orally), talinolol (30 mg intravenously and 100 mg orally), and digoxin plus talinolol orally, as well as digoxin plus talinolol intravenously, were assessed in five male and five female healthy volunteers (age range, 23 to 30 years; body weight, 60 to 95 kg) in a changeover study with at least a 7-day washout period. "
08/15/1982 - "It is reported on a severe talinolol intoxication of a 19-year-old female patient who on suicidal purpose had taken 1.25-1.5 g talinolol (cordanum) (= 25-30 mg/kg body weight). "
09/01/2004 - "To evaluate whether it also regulates the multidrug transporter proteins P-glycoprotein (P-gp) and multidrug resistance protein MRP2 in humans, duodenal expression of multidrug resistance gene MDR1 messenger ribonucleic acid (mRNA) and MRP2 mRNA, content of P-gp and MRP2, and disposition of the nonmetabolized P-gp substrate talinolol after intravenous (30 mg) and long-term oral administration (100 mg for 19 days) were assessed in 7 healthy subjects (age, 23-35 years; body weight, 64-93 kg) before and after comedication of carbamazepine (600 mg for 14-18 days). "
02/01/2005 - "To determine the dose dependency of the anti-anginal and antiischemic effects of the selective beta-blocker talinolol administered once-daily in a randomized, double-blind, placebo-controlled multicenter study in patients with stable angina pectoris. "
02/01/2005 - "Anti-anginal and anti-ischemic effects of the selective beta-blocker talinolol in patients with stable angina pectoris."
01/01/1982 - "[Use of the adrenergic selective beta 1-blocker cordanum in the treatment of patients with angina pectoris complicating pulmonary pathology]."
01/01/1981 - "[Comparative pharmacodynamic study of Cordanum and obzidan in stress angina pectoris patients]."
01/01/1981 - "The effect of different single doses of beta-blockers cordanum (talinolol) and obsidan was comparatively studied in 10 patients with angina pectoris of effort. "
10/01/2011 - "To study the potential interactions of naringin (NAR), talinolol (TAL) and protein-energy undernutrition (PEU) in the absorption process of saquinavir (SQV), perfusion experiments were performed in the small intestine of rats at different SQV concentrations. "
10/01/2011 - "In situ study of the effect of naringin, talinolol and protein-energy undernutrition on intestinal absorption of saquinavir in rats."